1

1 Strength of Statistical Evidence for the Efficacy of Cancer Drugs: A Bayesian Re-Analysis of 2 Randomized Trials Supporting FDA Approval. 3 Merle-Marie Pittelkow^{1,2*} (0000-0002-7487-7898), Maximilian Linde^{1,3} (0000-0001-8421-090X), 4 Ymkje Anna de Vries⁴ (0000-0003-4580-4873), Lars G. Hemkens^{5,6,7,8} (0000-0002-3444-1432), 5 Andreas M. Schmitt^{6,9} (0000-0002-9568-8164), Rob R. Meijer¹ (0000-0001-5368-992X), & Don van 6 7 Ravenzwaaij¹ (0000-0002-5030-4091) 8 9 ¹ Faculty of Behavioural and Social Sciences, University of Groningen, Groningen, the Netherlands 10 ² QUEST Center for Responsible Research, Berlin Institute of Health at Charité, Berlin, Germany 11 ³ GESIS - Leibniz Institute for the Social Sciences, Cologne, Germany 12 ⁴ Department of Child and Adolescent Psychiatry, University of Groningen, University Medical Center 13 Groningen, Groningen, The Netherlands 14 5 Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB). University 15 Hospital Basel and University of Basel, Basel, Switzerland 16 ⁶ Department of Clinical Research, University of Basel and University Hospital Basel, Basel, 17 Switzerland 18 ⁷ Meta-Research Innovation Center at Stanford (METRICS), Stanford University, Stanford, California, 19 USA 20 ⁸ Meta-Research Innovation Center Berlin (METRIC-B), Berlin Institute of Health, Berlin, Germany 21 ⁹ Department of Medical Oncology, University Hospital Basel, Basel, Switzerland. 22 23 *Correspondence to: merle-marie.pittelkow@bih-charite.de, Anna-Louisa-Karsch Straße 2, 10178

- 24 Berlin, Germany
- 25

2

26	ABSTRACT
27	Objective: To quantify the strength of statistical evidence of randomised controlled trials (RCTs) for
28	novel cancer drugs approved by the Food and Drug Administration (FDA) in the last two decades.
29	Study Design and Setting: We used data on overall survival (OS), progression-free survival (PFS), and
30	tumour response (TR) for novel cancer drugs approved for the first time by the FDA between January
31	2000 and December 2020. We assessed strength of statistical evidence by calculating Bayes Factors
32	(BFs) for all available endpoints, and we pooled evidence using Bayesian fixed-effect meta-analysis
33	for indications approved based on two RCTs. Strength of statistical evidence was compared between
34	endpoints, approval pathways, lines of treatment, and types of cancer.
35	Results: We analysed the available data from 82 RCTs corresponding to 68 indications supported by
36	a single RCT and seven indications supported by two RCTs. Median strength of statistical evidence
37	was ambiguous for OS (<i>BF</i> = 1.9; IQR 0.5-14.5), and strong for PFS (<i>BF</i> = 24,767.8; IQR 109.0-7.3*10 ⁶)
38	and TR (<i>BF</i> = 113.9; IQR 3.0-547,100). Overall, 44 indications (58.7%) were approved without clear
39	statistical evidence for OS improvements and seven indications (9.3%) were approved without
40	statistical evidence for improvements on any endpoint. Strength of statistical evidence was lower for
41	accelerated approval compared to non-accelerated approval across all three endpoints. No
42	meaningful differences were observed for line of treatment and cancer type.
43	Limitations: This analysis is limited to statistical evidence. We did not consider non-statistical factors
44	(e.g., risk of bias, quality of the evidence).
45	Conclusion: <i>BF</i> s offer novel insights into the strength of statistical evidence underlying cancer drug
46	approvals. Most novel cancer drugs lack strong statistical evidence that they improve OS, and a few
47	lack statistical evidence for efficacy altogether. These cases require a transparent and clear
48	explanation. When evidence is ambiguous, additional post-marketing trials could reduce
49	uncertainty.

50 *Keywords*: cancer drugs, evidence, regulatory approval, Bayes Factor, overall survival

3

51	BACKGROUND
52	For a new cancer drug to be marketed in the U.S., it needs to be endorsed by the Food and
53	Drug Administration (FDA). While many aspects of a drug's profile are considered in the approval
54	process, the statistical evaluation of efficacy plays a central role [1]. Cancer drugs are frequently
55	approved based on limited evidence, which increases uncertainty in clinical decision making [2–7].
56	Despite FDA guidelines suggesting that substantial evidence for efficacy based on two convincing
57	trials should be provided [8], approval for novel cancer drugs between 2000 and 2020 was typically
58	based on a single pivotal (i.e., efficacy determining) trial [2,7]. The understanding that this leads to a
59	reduced level of statistical evidence for efficacy is implicit. Previous work has considered the strength
60	of evidence indirectly considering effect sizes, number and kinds of trials, or qualitative evidence [2,7].
61	Explicit quantification of the statistical strength of evidence is missing. Another complication arises
62	from the FDA permitting surrogate endpoints, that is, outcomes that are no "direct measurement[s]
63	of clinical benefit but [] known to predict clinical benefit" (p. 16 [9]) such as overall survival (OS) but
64	are easier or faster to measure [10]. However, evidence that surrogate endpoints, like progression-
65	free survival (PFS) and tumour response (TR), predict overall survival in oncology is limited [10–12],
66	limiting the quality of the evidence available at the time of approval. Questions have been raised
67	whether the current statistical evidence for cancer drugs meets the FDA's requirement for showing
68	"meaningful therapeutic benefits" [3].
69	Explicit quantification of statistical strength of evidence for efficacy at the time of approval
70	can be achieved with Bayes Factors (BFs). Technically, BFs compare the likelihood of the observed
71	data under the null hypothesis (i.e., novel treatment does not improve outcomes) to the likelihood
72	of the observed data under an alternative hypothesis (e.g., novel treatment improves outcomes;

one-sided alternative hypothesis) [13-15]. The resulting ratio provides a relative measure of

statistical evidence for or against competing hypotheses (see Figure 1). For example, a BF of 1

indicates ambiguity as the observed study results are equally likely to have occurred if the novel

treatment improves OS or if the novel treatment does not improve OS. A BF of 10 indicates that the

73

74

75

4

- observed study results are ten times more likely to have occurred given that the novel treatment
- 78 improves OS than if it does not improve OS, whereas a BF of 0.1 indicates that the observed study
- results are ten times more likely to have occurred given that the novel treatment does not work
- 80 than if it does work.



82 Figure 1. Visual representation of the continuous properties and thresholds of the Bayes Factor in the 83 context of treatment evaluation. Bayes Factors above 3 indicate evidence in favour of the treatment 84 effect. Bayes Factors below 1/3 indicate evidence against the treatment effect. Note: These 85 thresholds have been proposed by methodological researchers and are not clinically informed 86 [15,24]. 87 Using the *BF*, we offer a different perspective on statistical evidence that may be more 88 intuitive than the traditional focus on statistical significance in frequentist frameworks. We take a 89 perspective like that of a clinician who wants to know if the results of a diagnostic test (here, the 90 approval trials) are more likely under a working diagnosis than under a differential diagnosis, which 91 is reflected by the BF. Moreover, using BFs, unlike traditional Frequentist testing, enables one to

92	differentiate between absence of evidence (i.e., ambiguous evidence) and evidence of absence (i.e.,
93	pro-null evidence). This project has two aims. First, we aim to quantify and describe the strength of
94	statistical evidence for efficacy associated with novel ¹ cancer drugs approved between 2000 and
95	2020 using BFs. Our second aim is to contrast strength of statistical evidence for efficacy between
96	endpoints, approval types, lines of treatment, and type of cancer, as standards for what constitutes
97	"sufficient" strength of statistical evidence for beneficial effects (and against harmful effects) at the
98	time of approval might differ. For example, one might accept more uncertainty and lower strength
99	of statistical evidence for 3rd or 4th line treatments than for 1st or 2 nd line treatments. Previous
100	reports also suggest that novel drugs for haematological cancers are more likely to be approved
101	based on single-arm trials and surrogate endpoints compared to solid cancers [2].
102	METHOD
103	Data and Registration
104	The aim and general approach of the project were registered at OSF (<u>https://osf.io/exyfd/</u>).
105	Analysis code and data are available from <u>https://ceit-cancer.org/</u> and OSF (<u>https://osf.io/4uhz7</u>). All
106	files needed to reproduce the analyses are available on OSF (<u>https://osf.io/qz7xy/</u>).
107	FDA Data
108	We used data from the CEIT-Cancer project (details provided elsewhere [16,17]). In short,
109	novel drugs and biological therapies receiving first approval for the treatment of any malignant
110	diseases between January 2000 and December 2020 and the corresponding FDA reviews (available
111	at <u>drugs@FDA</u>) were identified. For all RCTs evaluating the drug in the approved indication
112	(regardless of whether the trial was described as pivotal or not), the following data were extracted:
113	hazard ratios (HR) and associated 95% confidence intervals for OS and/or PFS; median OS and/or
114	PFS; number of events for OS, PFS and/or TR; sample size; line of treatment; approval pathway (i.e.,
115	priority review orphan design accelerated approval and breakthrough therapy designation): type

 $^{^{1}}$ Novel meaning first FDA approvals as opposed to label extensions or new indications of previously approved drugs.

6

116 of cancer; type of control; and type of blinding. The original data set also included single-arm

117 clinical trials that were explicitly described as pivotal. However, here we only considered data from

118 RCTs as single-arm trials do not provide comparative treatment outcomes.

119 Data Analysis

120 We used R version 4.1.2 [18]. We calculated BFs for all available endpoints per RCT. For OS 121 and PFS, we used the available summary statistics (i.e, HR, confidence interval of HR, sample size, 122 and number of events per group) to conduct a Bayesian Cox regression using the "baymedr" R 123 package [19]. We used a standard normal distribution that was truncated at 0 as the prior for beta 124 under the alternative hypothesis. For TR outcomes, BFs for chi-square tests were calculated using 125 the "BayesFactor" R package [20]. Under the null hypothesis, the prior for the proportion of TR was 126 a joint uniform distribution ranging from 0 to 1. Under the alternative hypothesis, the prior for the 127 proportion of TR was a uniform distribution ranging from 0 to 1 for each group independently [21]. 128 See supplement (section 1) for further details. For approvals based on two RCTs, we pooled available 129 outcomes for OS and PFS via fixed-effect meta-analysis using the "metaBMA" R package [22]. Under 130 the alternative hypothesis, the prior for the treatment effect was a default Cauchy distribution that was truncated at, with a location parameter of 0 and a scale parameter of $\frac{1}{\sqrt{2}}$ [23]. For TR, we pooled 131 132 the number of events and number of participants and calculated corresponding chi-square tests 133 using the "BayesFactor" R package with the same specifications as for single trial results. To describe 134 the strength of statistical evidence we adopted standard thresholds (see Figure 1). 135 The interpretation of pro-null BFs depends on the control group. Trials were classified as 136 inactively controlled if the control group received a placebo or no treatment even if all study 137 patients received treatment as usual (e.g., chemotherapy). Trials were classified as actively 138 controlled if the control group received another active treatment different from the experimental 139 group (e.g., an established treatment). In trials with inactive control groups, a pro-null BF means that 140 there is evidence that the drug performs comparable to or worse than placebo or no treatment, 141 indicating no efficacy of the novel drug. In trials with an active control group, interpreting pro-null

142	BFs is more difficult. Assuming that the active control group receives an effective therapy, a pro-null
143	BF can mean that the novel drug is ineffective, or just that it is not <i>more</i> effective than an
144	established effective treatment. Therefore, we discuss evidence per control condition whenever
145	possible. For the subgroup analysis of approval pathway, line of treatment, and type of cancer, we
146	did not separate results by control group as these subgroups were too small to be split further. We
147	describe results separately for drugs supported by a single RCT versus drugs supported by two RCTs,
148	as the two RCTs supporting a single drug may use different control groups (i.e., one using an inactive
149	control group and one using an active control group). This decision was not pre-registered.
150	Exploratory data analysis
151	We conducted four not pre-registered analyses, exploring: (1) the relationship between BFs
152	and effect sizes, (2) the relationship between BFs and sample size, and (3) the qualitative reasoning
153	behind endorsement decisions approved based on pro-null or ambiguous statistical evidence.
154	Rationales and details are provided in the supplement (section 3), and (4) in response to a reviewer
155	comment we examined the median strength of statistical evidence for primary endpoints and (5) the
156	relationship between evidential strength of OS and PFS, which is reported in the supplement.
157	RESULTS
158	The dataset contained data on 145 novel cancer drugs for 156 indications based on unique
159	186 trials. Of these, 75 indications (48.1%) received FDA approval without supporting evidence from
160	RCTs, 70 indications (44.9%) were supported by one, and 11 (7.1%) indications were supported by
161	two RCTs. Summary data were unavailable for 10 RCTs. Consequently, we analysed 82 RCTs
162	supporting approval for 75 indications of 75 novel cancer drugs, 68 (90.7%) supported by a single
163	RCT and 7 (8.5%) supported by two RCTs (see Figure S1). Of the 82 included trials, 72 trials assessed
164	OS (87.8%), 66 trials assessed PFS (80.5%), and 68 trials assessed TR (82.9%). Overall, 52 trials
165	provided data for all three endpoints (63.4%), 20 trials data for two endpoints (24.4%), and 10 trials
166	for only one endpoint (12.2%). Trial characteristics and individual <i>BF</i> s per trial and endpoint are
167	presented in the supplement (Table S1 and S2).

8

168 Approval decisions based on one RCT

- 169 Median evidential strength for drugs approved with one supportive RCT is provided in Table
- 170 1, and the distribution of *BF*s per endpoint and control group are presented in Figure 2.

171 Endpoints

- 172 Statistical evidence for a beneficial effect on at least one endpoint was moderate for five out
- of 68 (7.4%), and (very) strong for 49 out of 68 (86.8%) indications. The median BF for OS was 1.9
- 174 (IQR 0.5-14.5), for PFS 24,767.8 (IQR 109.0-7.3*10⁶) and for TR 113.9 (IQR 3.0 547,100).

175 Active control groups.

- 176 Trials with active control groups (*n* =22) had a median *BF* of 17.9 (IQR 1.0 12,220.0) across
- all three endpoints. Three (13.6%) indications lacked (very) strong statistical evidence for benefits on
- any endpoint, while five indications (22.7%) were supported by (very) strong statistical evidence for
- 179 benefits across all three endpoints.
- 180 Of the 19 indications with data available for OS, two (10.5%) were approved with pro-null or
- ambiguous statistical evidence for OS improvements without (very) strong evidence for
- 182 improvements on surrogate endpoints. Additionally, 12 indications (63.2%) were approved based on
- 183 pro-null or ambiguous statistical evidence for OS improvements but with (very) strong statistical
- evidence for improvements on at least one surrogate outcome. One indication (5.3%) was approved
- 185 based on moderate statistical evidence for OS improvements and (very) strong evidence for
- 186 improvements on the surrogate outcomes. The remaining four (21.1%) indications were approved
- 187 based on (very) strong statistical evidence for OS improvements.
- 188 For PFS or TR outcomes, the majority of trials indicated (very) strong statistical evidence for
- better treatment outcomes in the experimental compared to the control group (n = 15, 79.0% and n
- 190 = 16, 76.2% respectively; see also Figure 3). One drug (i.e., dasatinib) was approved based on
- 191 ambiguous statistical evidence for TR only.

	Overall		OS		PFS		TR	
	N (%)	Median BF (IQR)	N (%)	Median BF [IQR]	N (%)	Median BF [IQR]	N (%)	Median BF [IQR]
Overall	68 (100)		60 (100)	1.9 [0.5; 14.5]	57 (100)	24767.8 [109; 7287000]	57 (83.8)	114 [3; 547100]
Control group								
active	22 (32.4)	17.87 [1.0; 12220]	19 (31.7)	1.1 [0.3; 3.9]	19 (33.3)	245.2 [96.0; 31180]	21 (36.8)	32.0 [12.0; 2581000]
inactive	46 (67.6)	58.18 [2.0; 47080]	41 (68.3)	3.2 [0.5; 14.7]	38 (66.7)	84726.9 [233.0; 3.5*10 ⁸]	36 (63.2)	263 [2.0; 69880]
Accelerated approval								
yes	10 (14.7)	11.58 [0; 134]	7 (11.7)	0.5 [0.3; 16.9]	7 (12.3)	426.5 [52.0; 1165904]	7 (12.3)	32.0 [12.0; 2581000]
no	58 (85.3)	41.09 [1.0; 34220]	53 (88.3)	2.0 [0.8; 14.4]	50 (87.7)	26629.3 [233.0; 3.5*10 ⁸]	50 (87.7)	262.7 [2.0; 69880]
Line of treatment								
first	31 (45.6)	17.9 [2.0; 28900]	30 (50.0)	2.0 [0.9; 13.0]	23 (40.4)	28490.7 [105.0; 5.8 *10 ⁸]	24 (42.1)	621.5 [9.0; 5366000]
second	28 (41.2)	83.6 [1.0; 64850]	22 (36.7)	1.7 [0.5; 13.9]	26 (45.6)	2631.4 [418.0; 6060000]	26 (45.6)	123.9 [9.0; 435200]
≥third	9 (13.2)	5.00 [0.0; 4310]	8 (13.3)	1.7 [0.4; 12.1]	8 (14.0)	17761.5 [43.0; 2.1*10 ⁹]	7 (12.3)	1.1 [0.43; 1199]
C ancer type								
solid	49 (72.1)	32.03 [1.0; 29110]	46 (76.7)	2.1 [0.6; 15.0]	46 (80.7)	26629.3 [233; 6041000]	41 (71.9)	107.1 [2.0; 99710]
haematological	19 (27.9)	16.28 [1.0; 22690]	14 (23.3)	1.0 [0.3; 4.7]	11 (19.3)	20495.0 [72.0; 4.0 *10 ⁸]	16 (28.1)	1069.38 [15.0; 1426000]

Table 1. Descriptives for drug approvals supported by one RCT.

Note: The Overall column describes the values across all three endpoints. This means that a single trial can be included multiple times here (once for each available outcome).

193





- 196 and third quartiles are presented in vertical lines. Note that for PFS-active 2 effects, for PFS-inactive 2 effects, TR-active 1 effect, and TR-inactice 3 effects
- 197 were cut off.

10

198



199

Figure 3. Bar plot illustrating the proportion of trials supported by pro-null evidence $(BF<\frac{3}{2})$,

201 ambiguous evidence (1/3<BF<3), moderate pro-alternative evidence (3<BF<10), strong pro-alternative

202 evidence (10<BF<30) and very strong pro-alternative evidence per endpoint and control condition.

203 Counts are presented per category. Note that indications based on multiple trials are not included in

this figure.

205 Inactive control groups.

Trials with inactive control groups (placebo: n = 29; supportive care: 17) had a median *BF* of 58.2 (IQR 2 – 47,080.0) across all three endpoints. Two (4.3%) indications lacked (very) strong evidence for benefits on any endpoint (questioning the efficacy of the drug), while seven (17.1%) were supported by (very) strong statistical evidence for benefits across all three endpoints.

210 Of 41 indications with data available for OS, two (4.9%) were approved with pro-null or

ambiguous statistical evidence for improvements of OS and all other endpoints. Additionally, 18

212	drugs (43.9%) were approved based on pro-null or ambiguous statistical evidence for OS
213	improvements but with (very) strong statistical evidence for improvements on at least one surrogate
214	outcome. Eight (19.5%) indications were approved based on moderate statistical evidence for OS
215	improvements, of which five were supplemented with very strong statistical evidence for
216	improvements of at least one surrogate endpoint. The remaining 13 (31.7%) indications were
217	supported by (very) strong statistical evidence for OS.
218	The majority of indications were supported by very strong statistical evidence for
219	improvements of PFS or TR ($n = 34$, 89.5% and $n = 24$, 66.7% respectively; see also Figure 3). One
220	drug (neratinib maleate) was approved based on moderate statistical evidence for PFS
221	improvements.
222	Accelerated approval
223	Strength of statistical evidence was consistently lower for accelerated approvals ($n = 7$)
224	across endpoints (Figure 4). No indications with accelerated approval lacked or provided (very)
225	strong statistical evidence for improvements across all three endpoints. For indications that received
226	non-accelerated approval, 5 of 58 indications lacked strong evidence for improvements on any
227	endpoint, while 12 (out of 58) had strong or very strong statistical evidence for improvements across
228	all three endpoints.
229	Five out of seven (71.4%) accelerated approval decisions were based on pro-null or
230	ambiguous statistical evidence for OS improvements, compared to 29 out of 53 (54.7%) non-
231	accelerated approval decisions. Two (20.0%) accelerated approvals were based on pro-null evidence
232	for OS improvements (active control: nivolumab; placebo control: panitumumab).
233	For PFS, no trial provided pro-null statistical evidence. The proportion of ambiguous
234	statistical evidence was higher for accelerated approvals (2/7=28.6%) compared to non-accelerated
235	approval (5/50=10.0%). For TR, the proportion of pro-null evidence was similar across approval
236	pathways (accelerated: 1/7=14.3%; non-accelerated: 7/50=14.0%), but accelerated approvals were

more frequently (2/7=28.6%) based on ambiguous statistical evidence compared to non-accelerated



approvals (6/50=12.0%).





241 ambiguous evidence (¹/₃<BF<3), moderate pro-alternative evidence (3<BF<10), strong pro-alternative

242 evidence (10<BF<30) and very strong pro-alternative evidence per endpoint and approval pathway.

243 Note that indications based on multiple trials are not included in this figure

244 Line of treatment

245 For OS and PFS, strength of statistical evidence did not differ qualitatively between lines of

treatment (see Table 1). Although median strength of statistical evidence was greater for first-line

- treatment than for second-line treatment, IQRs mostly overlapped. For TR, strength of statistical
- evidence was lowest for trials supporting drugs approved for third or later line of treatment.
- 249 Cancer type

13

- 250 There was no difference in strength of statistical evidence between solid and haematological
- 251 cancer types (see Table 1).

252 Approvals based on two RCTs

253 Seven drugs were approved based on two RCTs (Table 2).

Table 2. BFs corresponding to the individual trials and the meta-analytic BF for all drugs with more than one RCT. BFs are presented per outcome. Yellow: $BF<\frac{3}{5}$; Light green: $\frac{3}{5} < BF<3$, Dark green: 3 < BF<10, Turquoise: 10 < BF<30; Dark blue: BF>30

Drug	Outcome	Strength of Statistical Evidence (BF)				
		RCT 1	RCT 2	Combined		
fulvestrant	OS	0.11	0.08	0.07		
	PFS	-	-	-		
	TR	0.28	0.09	0.33		
ruxolitinib phosphate	OS	0.95	0.81	0.89		
	PFS	0.53	-	-		
	TR	-	-	-		
trastuzumab emtansine*	OS	0.34	77.48	40.26		
	PFS	52279.93	-	-		
	TR	0.26	78.61	76.30		
bevacizumab	OS	2.74	768.15	2060.87		
	PFS	20.34	7.81*10 ⁸	1.38*10 ⁹		
	TR	2.70	5.89	25.6		
trifluridine tipiracil	OS	30.20	1865.24	29179.5		
	PFS	1.79*10 ¹⁵	-	-		
	TR	0.04	0.05	0.71		
binimetinib	OS	-	79.94			
	PFS	2.62	1677.46	4286.21		
	TR	4.49	2.11	45.4		
sorafenib tosylate	OS	-	4.48	-		
	PFS	697.30	5.96*10 ¹⁰	1.20**10 ¹⁰		
	TR	-	0.90	-		

*Please note that for this indication the participant groups differed between the RCTS; RCT1 was conducted in previously treated patients and RCT2 in previously untreated patients.

14

254	Two drugs (28.6%) were approved despite both trials providing pro-null or ambiguous
255	statistical evidence. Of these, fulvestrant was approved based on two RCTs indicating that the
256	treatment did not perform better than the active control on OS (meta $BF = 0.07$) and TR (meta $BF =$
257	0.12). The other, ruxolitinib, was approved based on two RCTs providing ambiguous statistical
258	evidence for OS (meta BF = 0.89) and ambiguous statistical evidence for PFS from one trial (BF =
259	0.53) ² . For the other five drugs, one RCT with ambiguous statistical evidence was supplemented by
260	another RCT with at least moderate statistical evidence in favour of a treatment effect.
261	Exploratory analysis
262	Relationship between strength of statistical evidence, effect size, and sample size
262 263	Relationship between strength of statistical evidence, effect size, and sample size In most cases, BF and 95% confidence intervals (CIs) were in agreement that an effect was
262 263 264	Relationship between strength of statistical evidence, effect size, and sample size In most cases, BF and 95% confidence intervals (CIs) were in agreement that an effect was pro-alternative (n=89) or ambiguous (n=28; i.e., 95% CI included the null). However, in 12 cases the
262 263 264 265	Relationship between strength of statistical evidence, effect size, and sample size In most cases, BF and 95% confidence intervals (CIs) were in agreement that an effect was pro-alternative (n=89) or ambiguous (n=28; i.e., 95% CI included the null). However, in 12 cases the 95% CI indicated uncertainty, while the <i>BF</i> was more informative, indicating absence of efficacy
262 263 264 265 266	Relationship between strength of statistical evidence, effect size, and sample size In most cases, BF and 95% confidence intervals (CIs) were in agreement that an effect was pro-alternative (n=89) or ambiguous (n=28; i.e., 95% CI included the null). However, in 12 cases the 95% CI indicated uncertainty, while the <i>BF</i> was more informative, indicating absence of efficacy (lower left and right quadrant in Figure 5). Additionally, there were 12 effects for which the HR and
262 263 264 265 266 267	Relationship between strength of statistical evidence, effect size, and sample size In most cases, BF and 95% confidence intervals (CIs) were in agreement that an effect was pro-alternative (n=89) or ambiguous (n=28; i.e., 95% CI included the null). However, in 12 cases the 95% CI indicated uncertainty, while the <i>BF</i> was more informative, indicating absence of efficacy (lower left and right quadrant in Figure 5). Additionally, there were 12 effects for which the HR and corresponding confidence intervals indicated efficacy, whereas the <i>BF</i> indicated ambiguous
262 263 264 265 266 267 268	Relationship between strength of statistical evidence, effect size, and sample size In most cases, BF and 95% confidence intervals (CIs) were in agreement that an effect was pro-alternative (n=89) or ambiguous (n=28; i.e., 95% CI included the null). However, in 12 cases the 95% CI indicated uncertainty, while the <i>BF</i> was more informative, indicating absence of efficacy (lower left and right quadrant in Figure 5). Additionally, there were 12 effects for which the HR and corresponding confidence intervals indicated efficacy, whereas the <i>BF</i> indicated ambiguous statistical evidence.

270 0.03).

 $^{^2}$ Note that for ruxolitinib phosphate evidence was pooled across trials with active and inactive comparators



272 Figure 5. BFs plotted against HR for the 68 indications with one RCT. Shapes indicate whether or not the confidence interval of the HR included.

17

273

274 Results from the exploratory qualitative analysis are presented in Table 3 and detailed in the

275 supplement (section 3).

Table 3. Reasons for drug approval mentioned for the seven drugs without statistical evidence for OS, PFS, or TR improvements. These themes were extracted via an exploratory qualitative thematic analysis.

Theme	Subthemes
Expected benefits over (non)-	- poor prognosis (despite available treatments)
existing treatments due to	- few or highly toxic available treatments
	- prior failed treatments
	- different administration (e.g., oral medication)
Tolerability	- limited crossover between treatment arms
	- low discontinuation rates
Positive interpretation of limited statistical evidence	 meaningful clinical differences (e.g., differences being statistically not significant but effect size deemed clinically meaningful)
	 convincing interim analyses (e.g., very small p-value interpreted as robust statistical evidence)
	- descriptive interpretation of premature survival analysis (e.g., eyeballing Kaplan-Meier survival curves or comparing percentages)
	 non-inferiority to control group (e.g., statistically non-significant superiority trial interpreted as successful non-inferiority trial)
Primary endpoints different from OS, PFS, or TR	 regulatory precedents (e.g., other drugs in the same group were approved based on this endpoint)
	- experience (e.g., the alternative endpoint was known to relate to OS or PFS)
Use of non-randomized evidence	- control group deemed unethical

276

277 Strength of statistical strength for primary endpoints

278 The median strength of statistical evidence was greater for OS and PFS when these

279 outcomes were considered primary, compared to when they were not, although the interquartile

280 IQRs mostly overlapped (see Table 4). Additional exploration regarding the differences in evidential

strength between outcomes depending on which outcome was considered primary are presented in

the supplement.

18

Endpoint	Primary	N trials	M _{participants} (SD)	M _{events} (exp; con)	median BF [IQR]
OS	yes	25	672 (328)	223; 178	14.4 [2.9; 303.2]
	no	47	422 (281)	65; 61	1.1 [0.4; 4.9]
PFS	yes	46	479 (417)	120; 123	24767.8 [109; 7287000]
	no	36	555 (399)	258; 193	745.7 [84.0; 1.2*10 ⁸]
TR	yes	12	285 (185)	52; 32	47.3 [2.0; 886.0]
	no	70	551 (425)	87; 42	45.0 [1.0; 69880]

Table 4. Median strength of statistical evidence for the primary and non-primary endpoints.

Note: exp: experimental arm; con: control arm; M_{events} refers to the primary outcome. These numbers are based both on individual trial endorsements and endorsements based on two RCTs combined. These numbers also combine trials for different cancer types which limits interpretability, as we expect differences in follow-up time and outcome choice between cancers.

284	
285	DISCUSSION
286	Quantifying the strength of statistical evidence for efficacy for pivotal RCTs supporting novel
287	cancer drugs approved by the FDA in the last two decades, we were able to provide explicit evidence
288	that strength of statistical evidence was substantially lower for OS, arguably the most important
289	outcome for cancer patients, compared to surrogate outcomes. Most indications (58.7%, 44/75)
290	were approved without clear statistical evidence for OS improvements. While most of these
291	indications (33/44) were supplemented by strong statistical evidence for improvements on at least
292	one surrogate endpoint (i.e., PFS/TR), uncertainties regarding OS improvements remain. The present
293	analysis using the BF was more informative than traditional measures of uncertainty such as the
294	confidence interval, because it allowed us to disambiguate between absence of evidence and
295	evidence of absence.
296	Strength of statistical evidence for efficacy differed between approval pathways but not
297	lines of treatment or cancer types. Although few indications were approved through accelerated

298	approval, our results suggest that weaker statistical evidence is accepted for accelerated approval
299	decisions. While the FDA accepts higher levels of uncertainty for accelerated approval decisions due
300	to the use of surrogate endpoints or intermediate clinical endpoints [25], we provide quantification
301	of how much uncertainty the FDA considers acceptable. This again highlights the importance of
302	timely post-approval studies to confirm efficacy. This need is also recognized in the Consolidated
303	Appropriations Act, 2023 (H.R. 2617), enabling the FDA to require post-approval studies to be
304	"underway prior to granting accelerated approval"[26]. It remains unclear how consistently the FDA
305	will react to post-approval trials failing to confirm clinical benefits. As of 2021, one third of the novel
306	cancer drugs receiving accelerated approval until 2020 but subsequently failing to improve primary
307	endpoints in their post-approval studies, remained on the drug's labelling (i.e., approved under the
308	accelerated pathway) or were converted to regular approval [27]. Clear regulations and consistent
309	action in response to post-approval trials is still lacking [27].
310	We observed indications receiving non-accelerated approval with absence of statistical
311	evidence or even statistical evidence for the absence of efficacy based on other considerations. For
312	example, favourable benefit-harm assessments were justified by expected benefits such as
313	improved quality of life and safety profiles. However, reporting of quality-of-life-outcomes is
314	incomplete [7] and not systematic, and a good safety profile is irrelevant in the absence of efficacy ³ .
315	In some cases, efficacy was determined in a manner different to the pre-registered protocol, for
316	instance through eyeballing Kaplan-Meier survival curves or comparing percentages. We observed
317	one instance in which a trial that failed to demonstrate superiority was re-interpreted as a non-
318	inferiority trial. Switching between superiority and non-inferiority interpretations after results are
319	known is problematic [28,29]. It would be preferable to supplement approval decisions with
320	additional trials, which would lead to stronger statistical evidence.

³ Please note that we are specifically referring to instances in which there is statistical evidence for the absence of efficacy. We do not mean instances in which there is no evidence that the novel treatment is better than standard care (i.e., a pro-null or ambiguous *BF* for active controlled trials).

20

321 In this paper, we primarily focused on cases with weak statistical evidence. However, there 322 was significant variation in the strength of evidence, with BFs for PFS and TR often suggesting solid 323 evidence for treatment effects. One might wonder, especially when time is of the essence, as it is 324 with cancer drugs, whether these drugs could be approved on the basis of weaker evidence. 325 However, the discussion of how much evidence is needed to determine efficacy based on surrogate 326 endpoints goes beyond the scope of this descriptive project, especially since this question cannot be 327 separated from the question of how well (BFs of) surrogate outcomes predict (BFs of) OS. These 328 questions warrant further investigation in future work. 329 **Strength and Limitations** 330 We used a comprehensive database of pre-approval trials, examined multiple endpoints, 331 and used a Bayesian approach to gain novel insights into the strength of evidence that allows for 332 interpretations that are in line with clinical decision making and may provide a more intuitive 333 perspective on evidence. The study also has several limitations. First, we focused on the statistical 334 evidence of RCTs supporting approval decisions. This does not reflect the full complexity of the 335 approval process and the variety of sources of evidence (e.g., quality of life, fewer side effects, method 336 of administration etc.) that might be considered. Nevertheless, RCTs generally provide the strongest 337 available evidence, as other sources of evidence (such as single-trial arms) are difficult to interpret. 338 Second, interpretation of the BF depends on the control group. While we differentiate between 339 active and inactive-controlled trials we did not classify whether comparators met the standard of 340 care. As a result, some of our BF might be an overestimation of the strength of evidence for efficacy. 341 Third, strength of statistical evidence is only one component of benefit assessment, and other 342 factors also play a role, including the effect size and risk of bias. Fourth, we restricted our analyses to 343 default priors to ensure comparability of our results across drug groups. Informed priors might be 344 used in future analysis of individual drugs to integrate the available evidence into the statistical 345 analysis. Lastly, we only included trials conducted to support approval decisions and did not include,

21

346	for instance, post-approval	studies. Therefore,	our results indicate the	strength of statistical
	, i - i - i - i - i - i - i - i - i - i	,		0

- 347 evidence available to support initial approval decisions and do not necessarily reflect the current
- 348 strength of statistical evidence.
- 349 Conclusion
- 350 Regulatory decision making could be improved by using *BFs* to distinguish between drugs
- with good statistical evidence, drugs that lack statistical evidence, and drugs with statistical evidence
- against efficacy. We found that across the board the level of evidence for beneficial effects on OS is
- 353 low. Average strength of statistical evidence on OS was moderate only if OS was considered the
- primary endpoint. While this suggests that evidence is better if the endpoint is considered primary,
- 355 OS should be important regardless of whether it is a primary outcome or not. Some drugs were even
- approved without supporting statistical evidence on either OS, PFS or TR. These cases require a
- transparent and clear explanation. In many cases the statistical evidence is ambiguous, calling for
- additional trials, before or after approval, to reduce this uncertainty.

22

360

List of Abbreviations

BF	Bayes Factor
FDA	Food and Drug Administration
OS	Overall survival
PFS	Progression-free survival
RCT	Randomized controlled trial
TR	Tumor response

361

363	Declarations
364	Ethics approval. This study involved publicly available trial-level data. No ethical approval was
365	needed.
366	Consent for publication. Not applicable.
367	Availability of data and materials. The data that support the findings of this study are available from
368	https://ceit-cancer.org/ and the OSF framework (https://osf.io/4uhz7) DOI 10.17605/OSF.IO/QZ7XY.
369	Competing interests. The authors declare that they have no competing interests.
370	Funding: This project is funded by an NWO Vidi grant to D. van Ravenzwaaij (016.Vidi.188.001).
371	Authors' contributions: MM.P.: Conceptualization, Data curation, Formal analysis, Methodology,
372	Project administration, Resources, Visualization, and Writing - original draft. <i>M.L</i> .: Formal analysis,
373	Software, and Writing - review & editing. Y.A.d.V.: Conceptualization, Supervision, and Writing -
374	review & editing. <i>L.G.H</i> .: Conceptualization, Investigation, and Writing - review & editing. <i>A.M.S</i> .:
375	Investigation and Writing - review & editing. <i>R.R.M.</i> : Conceptualization, Supervision, and Writing -
376	review & editing. D.v.R .: Conceptualization, Funding acquisition, Supervision, and Writing - review &
377	editing.
378	Patient and Public Involvement: Patients or the public were not involved in the design, or conduct,
379	or reporting, or dissemination plans of our research.
380	

24

381	Acknowledgements

- 382 We would like to thank Jonathan Kimmelman for his insightful and constructive comments during
- the review process.

385		References
386 387 388	1	Tafuri G, Stolk P, Trotta F, <i>et al</i> . How do the EMA and FDA decide which anticancer drugs make it to the market? A comparative qualitative study on decision makers' views. <i>Ann Oncol</i> . 2014;25:265–9.
389 390 391	2	Ladanie A, Schmitt AM, Speich B, <i>et al.</i> Clinical Trial Evidence Supporting US Food and Drug Administration Approval of Novel Cancer Therapies Between 2000 and 2016. <i>JAMA Netw Open.</i> 2020;3:e2024406.
392 393	3	Gyawali B, Hey SP, Kesselheim AS. Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval. <i>JAMA Intern Med</i> . 2019;179:906.
394 395	4	Salas-Vega S, Iliopoulos O, Mossialos E. Assessment of Overall Survival, Quality of Life, and Safety Benefits Associated With New Cancer Medicines. <i>JAMA Oncol</i> . 2017;3:382–90.
396 39 7	5	Vokinger KN, Kesselheim AS. Characteristics of trials and regulatory pathways leading to US approval of innovative vs. non-innovative oncology drugs. <i>Health Policy</i> . 2019;123:721–7.
398 399 400	6	Michaeli DT, Michaeli T. Overall Survival, Progression-Free Survival, and Tumor Response Benefit Supporting Initial US Food and Drug Administration Approval and Indication Extension of New Cancer Drugs, 2003-2021. <i>J Clin Oncol Off J Am Soc Clin Oncol</i> . 2022;JCO2200535.
401 402	7	Gloy V, Schmitt AM, Düblin P, <i>et al.</i> The Evidence Base of US Food and Drug Administration Approvals of Novel Cancer Therapies from 2000 to 2020. <i>Int J Cancer</i> . 2023;152:2474–84.
403 404	8	U.S. Food and Drug Administration. Guidance for Industry: E9 Statistical Principles for Clinical Trials. 1998. https://www.fda.gov/media/71336/download
405	9	U.S. Food and Drug Administration. Qualification Process for Drug Development Tools. 2020.
406 407	10	Kemp R, Prasad V. Surrogate endpoints in oncology: when are they acceptable for regulatory and clinical decisions, and are they currently overused? <i>BMC Med</i> . 2017;15:1–7.
408 409	11	Pignatti F, Jonsson B, Blumenthal G, <i>et al.</i> Assessment of benefits and risks in development of targeted therapies for cancer — The view of regulatory authorities. <i>Mol Oncol</i> . 2015;9:1034–41.
410 411 412	12	Prasad V, Kim C, Burotto M, <i>et al.</i> The Strength of Association Between Surrogate End Points and Survival in Oncology: A Systematic Review of Trial-Level Meta-analyses. <i>JAMA Intern Med</i> . 2015;175:1389–98.
413	13	Gronau QF, Ly A, Wagenmakers E-J. Informed Bayesian T-Tests. Am Stat. 2019;1–14.
414 415	14	Rouder JN, Speckman PL, Sun D, <i>et al.</i> Bayesian t tests for accepting and rejecting the null hypothesis. <i>Psychon Bull Rev</i> . 2009;16:225–37.
416	15	Jeffreys H. Theory of probability. Oxford: Oxford University Press 1961.
417 418 419	16	Ladanie A, Speich B, Naudet F, <i>et al</i> . The Comparative Effectiveness of Innovative Treatments for Cancer (CEIT-Cancer) project: Rationale and design of the database and the collection of evidence available at approval of novel drugs. <i>Trials</i> . 2018;19:1–13.

26

- 420 17 Ladanie A, Ewald H, Kasenda B, *et al.* How to use FDA drug approval documents for evidence
 421 syntheses. *BMJ*. 2018;362:k2815.
- R Core Team. *R: A Language and Environment for Statistical Computing*. Vienna, Austria: R
 Foundation for Statistical Computing 2021. https://www.R-project.org/
- Linde M, van Ravenzwaaij D, Tendeiro JN. *baymedr: Computation of Bayes Factors for Common Biomedical Designs*. 2022. https://github.com/maxlinde/baymedr
- 426 20 Morey RD, Rouder JN, Jamil T, *et al.* BayesFactor: Computation of Bayes Factors for Common 427 Designs. 2022. https://CRAN.R-project.org/package=BayesFactor (accessed 19 July 2022)
- 428 21 Jamil T, Ly A, Morey RD, *et al.* Default "Gunel and Dickey" Bayes factors for contingency tables.
 429 *Behav Res Methods*. 2017;49:638–52.
- 43022Heck DW, Gronau QF, Wagenmakers E-J. metaBMA: Bayesian model averaging for random and431fixed effects meta-analysis. Retrieved Doi. 2017. https://cran.r-
- 432 project.org/web/packages/metaBMA/metaBMA.pdf (accessed 20 March 2021)
- 433 23 Gronau QF, Heck DW, Berkhout SW, *et al.* A Primer on Bayesian Model-Averaged Meta-Analysis.
 434 Adv Methods Pract Psychol Sci. 2021;4:25152459211031256.
- 435 24 Lee MD, Wagenmakers E-J. *Bayesian cognitive modeling: A practical course*. Cambridge
 436 university press 2014.
- 437 25 U.S. Food and Drug Administration. Accelerated Approval. FDA. 2023.
 438 https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority439 review/accelerated-approval (accessed 30 January 2024)
- 440 26 New FDA Reform Legislation: Congress Gifts a "FDORA" for the Holidays. 2023.
- 441 https://www.ropesgray.com/en/newsroom/alerts/2023/01/new-fda-reform-legislation 442 congress-gifts-a-fdora-for-the-holidays (accessed 16 February 2023)
- 443 27 Gyawali B, Rome BN, Kesselheim AS. Regulatory and clinical consequences of negative
 444 confirmatory trials of accelerated approval cancer drugs: retrospective observational study.
 445 *BMJ*. 2021;374:n1959.
- 446 28 U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Non-Inferiority
 447 Clinical Trials to Establish Effectiveness Guidance for Industry. 2016.
 448 https://www.fda.gov/media/78504/download
- Committee for Proprietary Medicinal Products. Points to consider on switching between
 superiority and non-inferiority. *Br J Clin Pharmacol*. 2001;52:223–8.